Literature DB >> 20014947

Expression and mutation analysis of her2 in head and neck squamous cell carcinoma.

Mahmoud A L Sheikh Ali1, Mehmet Gunduz, Esra Gunduz, Ryo Tamamura, Levent Bekir Beder, Naoki Katase, Omer Faruk Hatipoglu, Kunihiro Fukushima, Noboru Yamanaka, Kenji Shimizu, Hitoshi Nagatsuka.   

Abstract

We analyzed mutation and expression status of human epidermal growth factor receptor 2 (Her2) in head and neck squamous cell carcinoma (HNSCC) using single strand conformation polymorphism (SSCP) mutation analysis and immunohistochemistry (IHC). Mutations were absent in all 85 cases. Out of 57 cases available for IHC, Her2 protein expression was negative (0) in 40 tumors (70%). Seventeen tumors (29.8%) expressed Her2, among these 13 tumors (22.8%) showed a weak (+1) expression and 4 (7%) showed a moderate expression (+2), none showed a strong (+3) expression. There was not a significant association between expression and any of the patients' clinical variables or prognosis. Our results suggest that Her2 may not be useful as a molecular target in HNSCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20014947     DOI: 10.3109/07357900903476778

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  5 in total

1.  Head and neck squamous cell carcinoma in pregnant women.

Authors:  Anna M Eliassen; Samantha J Hauff; Alice L Tang; Dafydd H Thomas; Jonathan B McHugh; Heather M Walline; Jay Stoerker; Jessica H Maxwell; Francis P Worden; Avraham Eisbruch; Michael J Czerwinski; Silvana M Papagerakis; Douglas B Chepeha; Carol R Bradford; David A Hanauer; Thomas E Carey; Mark E Prince
Journal:  Head Neck       Date:  2012-03-16       Impact factor: 3.147

Review 2.  HER2 as a therapeutic target in head and neck squamous cell carcinoma.

Authors:  Netanya I Pollock; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2014-11-25       Impact factor: 12.531

Review 3.  Targeting HER (ERBB) signaling in head and neck cancer: An essential update.

Authors:  Jun Zhang; Nabil F Saba; Georgia Zhuo Chen; Dong M Shin
Journal:  Mol Aspects Med       Date:  2015-07-07

Review 4.  The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo.

Authors:  Huei Leng Helena Ng; Aiping Lu; Ge Lin; Ling Qin; Zhijun Yang
Journal:  Int J Mol Sci       Date:  2014-12-24       Impact factor: 5.923

5.  Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma.

Authors:  Giovanni Almadori; Antonella Coli; Eugenio De Corso; Dario Antonio Mele; Stefano Settimi; Giovanni Di Cintio; Francesca Brigato; Domenico Scannone; Thomas E Carey; Gaetano Paludetti; Libero Lauriola; Franco Oreste Ranelletti
Journal:  J Transl Med       Date:  2021-09-27       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.